Premium
Brimonidine Toxicity Secondary to Topical Use for an Ulcerated Hemangioma
Author(s) -
Gill Kamalvir,
Bayart Cheryl,
Desai Ritu,
Golden Alex,
Raimer Patricia,
Tamburro Joan
Publication year - 2016
Publication title -
pediatric dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 73
eISSN - 1525-1470
pISSN - 0736-8046
DOI - 10.1111/pde.12868
Subject(s) - brimonidine , medicine , timolol , anesthesia , ocular hypertension , glaucoma , intraocular pressure , ophthalmology , dermatology
Combigan (Allergan, Irvine, CA) is an ophthalmic solution that combines 0.2% brimonidine, a selective α‐2 adrenergic agonist, with 0.5% timolol, a nonselective β‐adrenergic antagonist. It is approved for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. There have been recent reports of successful treatment of superficial infantile hemangiomas (IHs) using Combigan topically. We report the case of a 2‐month‐old girl who developed life‐threatening brimonidine toxicity requiring intubation and mechanical ventilation secondary to central nervous system depression and apnea after topical application to an ulcerated IH.